News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Genetics, Inc. (SGEN) Initiates Phase 1 Trial of SGN-CD33A in Acute Myeloid Leukemia (AML)



7/15/2013 10:07:13 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today announced initiation of a phase 1 clinical trial of SGN-CD33A for patients with acute myeloid leukemia (AML). SGN-CD33A is a novel antibody-drug conjugate (ADC) utilizing Seattle Genetics’ newest ADC technology targeted to CD33, which is expressed on most AML cells. The CD33 antibody is attached to a highly potent cytotoxic DNA-crosslinking agent, a pyrrolobenzodiazepine (PBD) dimer, via a proprietary site-specific conjugation technology to a monoclonal antibody with engineered cysteines (EC-mAb). The trial is designed to assess the safety and anti-leukemia activity of SGN-CD33A.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES